VYNT Insider Trading Activity and SEC Form 4 Filings
VYNT insider trading summary
No open-market insider purchases or sales of Vyant Bio, Inc. (VYNT) have been reported on SEC Form 4 in the past 12 months.
Latest VYNT insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Nov 18, 2022 | Geoffrey E. Harris | Director | Sell | $888 (666 @ $1.33) |
| Nov 18, 2022 | Geoffrey E. Harris | Director | Sell | $133 (99 @ $1.34) |
| Dec 6, 2021 | Marcus Boehm | Director | Buy | $8K (5,000 @ $1.69) |
| Nov 24, 2021 | John A Roberts | Chief Executive Officer | Buy | $10K (5,000 @ $2.02) |
| Nov 23, 2021 | Andrew D.C. LaFrence | Chief Financial Officer | Buy | $10K (5,000 @ $2.00) |
| Nov 22, 2021 | Yung-Ping Yeh | Chief Innovation Officer | Buy | $1K (500 @ $2.05) |
| Oct 28, 2021 | Robert Thomas Fremeau Jr. | Chief Scientific Officer | Buy | $2K (1,000 @ $2.19) |
| Oct 27, 2021 | Marcus Boehm | Director | Buy | $11K (5,000 @ $2.10) |
| Sep 29, 2021 | Marcus Boehm | Director | Buy | $12K (5,000 @ $2.44) |
| Aug 25, 2021 | Marcus Boehm | Director | Buy | $13K (5,000 @ $2.58) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.